September 22, 2020 -- Serum Institute of India has begun manufacturing Codagenix's COVID-19 vaccine candidate, CDX-005.
The vaccine is delivered nasally and is a live-attenuated candidate for SARS-CoV-2, the company said. CDX-005 was engineered using the company's proprietary codon deoptimization software platform, which allowed them to recode the SARS-CoV-2 virus genome by inserting hundreds of mutations.
Preclinical animal studies have been successfully completed and a phase I human clinical trial will begin in the U.K. by the end of this year, according to Codagenix.
The Serum Institute, the world's largest supplier of vaccines globally at more than 1.5 billion doses, has begun manufacturing for large-scale safety and efficacy studies and to prepare to meet global vaccine supply requirements after receiving the necessary approval from the Review Committee on Genetic Manipulation of India's Department of Biotechnology.
Copyright © 2020 scienceboard.net